Floatz logo

PI3K/MTOR INHIBITOR LY3023414

Recurrent Hepatoblastoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

43 Active assets in the Recurrent Hepatoblastoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
University of Birmingham
Phase 3BB
ETOPOSIDE
Children's Oncology Group
Phase 3BB
Eloxatin
Children's Oncology Group
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
Carboplatin
Children's Oncology Group
Phase 3BB

View all 50 →

Same molecule, other indications

PI3K/MTOR INHIBITOR LY3023414 is also rated in:

rhabdoid tumorDormant
B
Indicative ·
57 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
B
Indicative ·
57 / 100
View asset →
Langerhans cell histiocytosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →